Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Migraine-Pipeline Review, H2 2016

Migraine-Pipeline Review, H2 2016


  Request for Sample Report

Executive Summary

Migraine-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine-Pipeline Review, H2 2016, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 12, 14, 14, 20, 8 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 3 molecules, respectively.Migraine.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Migraine Overview 10

Therapeutics Development 11

Pipeline Products for Migraine-Overview 11

Pipeline Products for Migraine-Comparative Analysis 12

Migraine-Therapeutics under Development by Companies 13

Migraine-Therapeutics under Investigation by Universities/Institutes 17

Migraine-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Migraine-Products under Development by Companies 22

Migraine-Products under Investigation by Universities/Institutes 26

Migraine-Companies Involved in Therapeutics Development 27

Achelios Therapeutics Inc 27

Acorda Therapeutics Inc 28

Afferent Pharmaceuticals Inc 29

Alder Biopharmaceuticals Inc 30

Allergan Plc 31

Amgen Inc 32

Aralez Pharmaceuticals Inc 33

Astellas Pharma Inc 34

Biofrontera AG 35

BioHealthonomics Inc 36

Bristol-Myers Squibb Company 37

Charleston Laboratories Inc 38

CoLucid Pharmaceuticals Inc 39

Corium International Inc 40

Eli Lilly and Company 41

Impel NeuroPharma Inc 42

InStar Technologies AS 43

Klaria Pharma Holding AB 44

Medestea Research & Production SpA 45

Merck & Co Inc 46

Mithra Pharmaceuticals SA 47

Monosol Rx LLC 48

NAL Pharmaceuticals Ltd 49

Noxxon Pharma AG 50

Otsuka Holdings Co Ltd 51

Promius Pharma LLC 52

RedHill Biopharma Ltd 53

Revance Therapeutics Inc 54

Shin Nippon Biomedical Laboratories Ltd 55

Strategic Science & Technologies LLC 56

Suda Ltd 57

Teva Pharmaceutical Industries Ltd 58

TheraJect Inc 59

Tonix Pharmaceuticals Holding Corp 60

Trevena Inc 61

Trigemina Inc 62

TrioxBio Inc 63

Vertex Pharmaceuticals Inc 64

Xenon Pharmaceuticals Inc 65

Zosano Pharma Corp 66

Migraine-Therapeutics Assessment 67

Assessment by Monotherapy Products 67

Assessment by Combination Products 68

Assessment by Target 69

Assessment by Mechanism of Action 74

Assessment by Route of Administration 79

Assessment by Molecule Type 81

Drug Profiles 83

(dextromethorphan + quinidine sulfate)-Drug Profile 83

(naproxen sodium + sumatriptan succinate)-Drug Profile 88

(promethazine [INN] + sumatriptan succinate)-Drug Profile 90

AA-71-Drug Profile 91

AF-130-Drug Profile 92

AGN-241689-Drug Profile 93

ALD-1910-Drug Profile 94

ALD-403-Drug Profile 95

AMG-301-Drug Profile 99

AST-003-Drug Profile 100

Atogepant-Drug Profile 101

BF-1-Drug Profile 102

C-012-Drug Profile 103

cloxyquin-Drug Profile 104

Deina-Drug Profile 105

dexisometheptene-Drug Profile 106

DFN-02-Drug Profile 107

DFN-10-Drug Profile 108

DFN-14-Drug Profile 109

DFN-15-Drug Profile 110

DFN-19-Drug Profile 111

DFN-42-Drug Profile 112

dihydroergotamine mesylate-Drug Profile 113

dihydroergotamine mesylate-Drug Profile 118

DIS-COM-TROP-Drug Profile 119

DORA-12-Drug Profile 120

Drug 1 for Migraine and Cancer Pain-Drug Profile 121

Drug 2 for Migraine and Cancer Pain-Drug Profile 122

Drug 3 for Migraine and Cancer Pain-Drug Profile 123

Drug for Migraine-Drug Profile 124

Drug for Migraine and Cancer Pain-Drug Profile 125

erenumab-Drug Profile 126

Estetrol-Drug Profile 129

flunarizine hydrochloride-Drug Profile 132

galcanezumab-Drug Profile 133

histamine dihydrochloride-Drug Profile 135

ketoprofen-Drug Profile 136

KL-00204-Drug Profile 138

lasmiditan succinate-Drug Profile 139

MK-8031-Drug Profile 144

MTR-106-Drug Profile 145

Nociceptin-Drug Profile 146

NOXL-41-Drug Profile 147

NXN-188-Drug Profile 148

NXN-462-Drug Profile 150

oxytocin-Drug Profile 151

picotamide-Drug Profile 153

propofol hemisuccinate-Drug Profile 154

Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine-Drug Profile 155

rizatriptan benzoate-Drug Profile 156

rizatriptan benzoate-Drug Profile 159

rizatriptan benzoate-Drug Profile 160

RT-001-Drug Profile 161

Small Molecule to Antagonize CALCRL for Migraine-Drug Profile 163

Small Molecule to Antagonize CGRP Receptor for Migraine-Drug Profile 164

Small Molecule to Antagonize Kappa Opioid Receptor for Migraine-Drug Profile 165

Small Molecule to Inhibit CGRP for Migraine-Drug Profile 166

Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus-Drug Profile 167

Small Molecule to Inhibit nNOS and NET for Migraine and Neuropathic Pain-Drug Profile 168

Small Molecules to Agonize CB2 for Chronic Pain and Migraine-Drug Profile 169

Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine-Drug Profile 170

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine-Drug Profile 171

Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain-Drug Profile 172

SST-8055-Drug Profile 173

sumatriptan succinate-Drug Profile 174

sumatriptan succinate-Drug Profile 176

sumatriptan succinate-Drug Profile 177

sumatriptan succinate-Drug Profile 178

TEV-48125-Drug Profile 179

Tribarcina-Drug Profile 183

TRV-250-Drug Profile 184

ubrogepant-Drug Profile 185

zolmitriptan-Drug Profile 187

zolmitriptan-Drug Profile 188

zolmitriptan-Drug Profile 190

zolmitriptan-Drug Profile 191

Migraine-Dormant Projects 192

Migraine-Discontinued Products 199

Migraine-Product Development Milestones 200

Featured News & Press Releases 200

Appendix 215

Methodology 215

Coverage 215

Secondary Research 215

Primary Research 215

Expert Panel Validation 215

Contact Us 215

Disclaimer 216

List of Figures

Number of Products under Development for Migraine, H2 2016 16

Number of Products under Development for Migraine-Comparative Analysis, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Products, H2 2016 25

Assessment by Monotherapy Products, H2 2016 72

Assessment by Combination Products, H2 2016 73

Number of Products by Top 10 Targets, H2 2016 74

Number of Products by Stage and Top 10 Targets, H2 2016 74

Number of Products by Top 10 Mechanism of Actions, H2 2016 79

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 79

Number of Products by Routes of Administration, H2 2016 84

Number of Products by Stage and Routes of Administration, H2 2016 84

Number of Products by Molecule Types, H2 2016 86

Number of Products by Stage and Molecule Types, H2 2016 86

List of Tables

Number of Products under Development for Migraine, H2 2016 16

Number of Products under Development for Migraine-Comparative Analysis, H2 2016 17

Number of Products under Development by Companies, H2 2016 19

Number of Products under Development by Companies, H2 2016 (Contd..1) 20

Number of Products under Development by Companies, H2 2016 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 23

Comparative Analysis by Clinical Stage Development, H2 2016 24

Comparative Analysis by Early Stage Development, H2 2016 25

Comparative Analysis by Unknown Stage Development, H2 2016 26

Products under Development by Companies, H2 2016 27

Products under Development by Companies, H2 2016 (Contd..1) 28

Products under Development by Companies, H2 2016 (Contd..2) 29

Products under Development by Companies, H2 2016 (Contd..3) 30

Products under Investigation by Universities/Institutes, H2 2016 31

Migraine-Pipeline by Achelios Therapeutics Inc, H2 2016 32

Migraine-Pipeline by Acorda Therapeutics Inc, H2 2016 33

Migraine-Pipeline by Afferent Pharmaceuticals Inc, H2 2016 34

Migraine-Pipeline by Alder Biopharmaceuticals Inc, H2 2016 35

Migraine-Pipeline by Allergan Plc, H2 2016 36

Migraine-Pipeline by Amgen Inc, H2 2016 37

Migraine-Pipeline by Aralez Pharmaceuticals Inc, H2 2016 38

Migraine-Pipeline by Astellas Pharma Inc, H2 2016 39

Migraine-Pipeline by Biofrontera AG, H2 2016 40

Migraine-Pipeline by BioHealthonomics Inc, H2 2016 41

Migraine-Pipeline by Bristol-Myers Squibb Company, H2 2016 42

Migraine-Pipeline by Charleston Laboratories Inc, H2 2016 43

Migraine-Pipeline by CoLucid Pharmaceuticals Inc, H2 2016 44

Migraine-Pipeline by Corium International Inc, H2 2016 45

Migraine-Pipeline by Eli Lilly and Company, H2 2016 46

Migraine-Pipeline by Impel NeuroPharma Inc, H2 2016 47

Migraine-Pipeline by InStar Technologies AS, H2 2016 48

Migraine-Pipeline by Klaria Pharma Holding AB, H2 2016 49

Migraine-Pipeline by Medestea Research & Production SpA, H2 2016 50

Migraine-Pipeline by Merck & Co Inc, H2 2016 51

Migraine-Pipeline by Mithra Pharmaceuticals SA, H2 2016 52

Migraine-Pipeline by Monosol Rx LLC, H2 2016 53

Migraine-Pipeline by NAL Pharmaceuticals Ltd, H2 2016 54

Migraine-Pipeline by Noxxon Pharma AG, H2 2016 55

Migraine-Pipeline by Otsuka Holdings Co Ltd, H2 2016 56

Migraine-Pipeline by Promius Pharma LLC, H2 2016 57

Migraine-Pipeline by RedHill Biopharma Ltd, H2 2016 58

Migraine-Pipeline by Revance Therapeutics Inc, H2 2016 59

Migraine-Pipeline by Shin Nippon Biomedical Laboratories Ltd, H2 2016 60

Migraine-Pipeline by Strategic Science & Technologies LLC, H2 2016 61

Migraine-Pipeline by Suda Ltd, H2 2016 62

Migraine-Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 63

Migraine-Pipeline by TheraJect Inc, H2 2016 64

Migraine-Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2016 65

Migraine-Pipeline by Trevena Inc, H2 2016 66

Migraine-Pipeline by Trigemina Inc, H2 2016 67

Migraine-Pipeline by TrioxBio Inc, H2 2016 68

Migraine-Pipeline by Vertex Pharmaceuticals Inc, H2 2016 69

Migraine-Pipeline by Xenon Pharmaceuticals Inc, H2 2016 70

Migraine-Pipeline by Zosano Pharma Corp, H2 2016 71

Assessment by Monotherapy Products, H2 2016 72

Assessment by Combination Products, H2 2016 73

Number of Products by Stage and Target, H2 2016 75

Number of Products by Stage and Mechanism of Action, H2 2016 80

Number of Products by Stage and Route of Administration, H2 2016 85

Number of Products by Stage and Molecule Type, H2 2016 87

Migraine-Dormant Projects, H2 2016 197

Migraine-Dormant Projects (Contd..1), H2 2016 198

Migraine-Dormant Projects (Contd..2), H2 2016 199

Migraine-Dormant Projects (Contd..3), H2 2016 200

Migraine-Dormant Projects (Contd..4), H2 2016 201

Migraine-Dormant Projects (Contd..5), H2 2016 202

Migraine-Dormant Projects (Contd..6), H2 2016 203

Migraine-Discontinued Products, H2 2016 204

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Achelios Therapeutics Inc , Acorda Therapeutics Inc , Afferent Pharmaceuticals Inc , Alder Biopharmaceuticals Inc , Allergan Plc , Amgen Inc , Aralez Pharmaceuticals Inc , Astellas Pharma Inc , Biofrontera AG , BioHealthonomics Inc , Bristol-Myers Squibb Company, Charleston Laboratories Inc , CoLucid Pharmaceuticals Inc , Corium International Inc , Eli Lilly and Company , Impel NeuroPharma Inc , InStar Technologies AS , Klaria Pharma Holding AB , Medestea Research & Production SpA, Merck & Co Inc , Mithra Pharmaceuticals SA , Monosol Rx LLC , NAL Pharmaceuticals Ltd , Noxxon Pharma AG , Otsuka Holdings Co Ltd , Promius Pharma LLC , RedHill Biopharma Ltd , Revance Therapeutics Inc , Shin Nippon Biomedical Laboratories Ltd, Strategic Science & Technologies LLC, Suda Ltd , Teva Pharmaceutical Industries Ltd, TheraJect Inc , Tonix Pharmaceuticals Holding Corp, Trevena Inc , Trigemina Inc , TrioxBio Inc , Vertex Pharmaceuticals Inc , Xenon Pharmaceuticals Inc , Zosano Pharma Corp

Migraine Therapeutic Products under Development, Key Players in Migraine Therapeutics, Migraine Pipeline Overview, Migraine Pipeline, Migraine Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com